Aripiprazole is a partial dopamine agonist of the second generation class of atypical antipsychotics. Used for the treatment of schizophrenia, bipolar disorder and major depressive disorder; it treats acute manic and mixed episodes associated with bipolar disorder.

Aripiprazole is metabolized by CYP3A4 and CYP2D6. Dose adjustments are required for known CYP2D6 poor metabolizers and for patients taking CYP3A4 inhibitors, CYP2D6 inhibitors, or CYP3A4 inducers for more than 2 weeks. Peer-reviewed Consensus on Pharmacogenomic Testing in Psychiatry endorse use of standardized pharmacogenetic reporting for CYP2C19, CYP2D6 and HLA alleles according to CPIC guidelines for psychiatric medications.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders.

• https://www.pharmgkb.org/chemical/PA10026/prescribingInfo
• https://www.nature.com/articles/s41431-023-01347-3
• https://www.ncbi.nlm.nih.gov/books/NBK385288/
• http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac
• https://api.pharmgkb.org/v1/download/file/attachment/Aripiprazole_HCSC_05_06_15.pdf
• https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1288-1061